CryoPort, Inc. (NASDAQ:CYRX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of CryoPort, Inc. (NASDAQ:CYRX) have earned an average recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $12.8333.

CYRX has been the topic of a number of recent analyst reports. UBS Group upped their target price on CryoPort from $11.00 to $12.50 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a report on Monday, December 29th. Needham & Company LLC raised their price objective on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Finally, BTIG Research boosted their target price on shares of CryoPort from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th.

Insiders Place Their Bets

In other CryoPort news, Director Ramkumar Mandalam sold 11,570 shares of the company’s stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $9.99, for a total transaction of $115,584.30. Following the sale, the director owned 80,758 shares in the company, valued at $806,772.42. This represents a 12.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 10.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CryoPort

A number of institutional investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC lifted its stake in CryoPort by 299.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company’s stock worth $27,000 after purchasing an additional 2,729 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of CryoPort by 300.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after buying an additional 4,375 shares during the last quarter. Whittier Trust Co. of Nevada Inc. bought a new position in shares of CryoPort in the 3rd quarter worth about $53,000. ProShare Advisors LLC acquired a new position in shares of CryoPort in the 2nd quarter valued at about $75,000. Finally, AlphaQuest LLC bought a new stake in shares of CryoPort during the 3rd quarter valued at about $79,000. 92.90% of the stock is currently owned by institutional investors.

CryoPort Stock Performance

NASDAQ:CYRX opened at $10.74 on Wednesday. The company has a debt-to-equity ratio of 0.40, a current ratio of 15.77 and a quick ratio of 15.01. The firm has a 50-day moving average of $9.43 and a two-hundred day moving average of $9.01. The stock has a market cap of $537.75 million, a P/E ratio of 9.18 and a beta of 1.54. CryoPort has a 1-year low of $4.58 and a 1-year high of $11.44.

CryoPort (NASDAQ:CYRX) last announced its earnings results on Tuesday, November 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. The business had revenue of $44.23 million for the quarter, compared to analyst estimates of $41.22 million. CryoPort had a negative return on equity of 11.07% and a net margin of 35.57%. On average, research analysts expect that CryoPort will post -0.99 earnings per share for the current fiscal year.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.